Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage.
Alteri C, Surdo M, Bellocchi MC, Saccomandi P, Continenza F, Armenia D, Parrotta L, Carioti L, Costa G, Fourati S, Di Santo F, Scutari R, Barbaliscia S, Fedele V, Carta S, Balestra E, Alcaro S, Marcelin AG, Calvez V, Ceccherini-Silberstein F, Artese A, Perno CF, Svicher V. Alteri C, et al. Among authors: fourati s. Antimicrob Agents Chemother. 2015 Aug;59(8):4870-81. doi: 10.1128/AAC.00137-15. Epub 2015 Jun 8. Antimicrob Agents Chemother. 2015. PMID: 26055363 Free PMC article.
Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
Soulié C, Fourati S, Lambert-Niclot S, Malet I, Wirden M, Tubiana R, Valantin MA, Katlama C, Calvez V, Marcelin AG. Soulié C, et al. Among authors: fourati s. J Antimicrob Chemother. 2010 Apr;65(4):749-51. doi: 10.1093/jac/dkq029. Epub 2010 Feb 11. J Antimicrob Chemother. 2010. PMID: 20150182
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
Malet I, Wirden M, Fourati S, Armenia D, Masquelier B, Fabeni L, Sayon S, Katlama C, Perno CF, Calvez V, Marcelin AG, Ceccherini-Silberstein F. Malet I, et al. Among authors: fourati s. J Antimicrob Chemother. 2011 Jul;66(7):1481-3. doi: 10.1093/jac/dkr152. Epub 2011 Apr 7. J Antimicrob Chemother. 2011. PMID: 21474479 Free article.
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vézinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG. Malet I, et al. Among authors: fourati s. J Antimicrob Chemother. 2011 Dec;66(12):2827-30. doi: 10.1093/jac/dkr389. Epub 2011 Sep 19. J Antimicrob Chemother. 2011. PMID: 21933786
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors.
Fourati S, Visseaux B, Armenia D, Morand-Joubert L, Artese A, Charpentier C, Van Den Eede P, Costa G, Alcaro S, Wirden M, Perno CF, Ceccherini Silberstein F, Descamps D, Calvez V, Marcelin AG. Fourati S, et al. J Antimicrob Chemother. 2013 Oct;68(10):2199-204. doi: 10.1093/jac/dkt200. Epub 2013 Jun 7. J Antimicrob Chemother. 2013. PMID: 23749955
Pitfalls of HIV genotypic tropism testing after treatment interruption.
Wirden M, Soulié C, Fourati S, Valantin MA, Simon A, Ktorza N, Tubiana R, Bonmarchand M, Schneider L, Calvez V, Katlama C, Marcelin AG. Wirden M, et al. Among authors: fourati s. J Antimicrob Chemother. 2013 Jan;68(1):188-9. doi: 10.1093/jac/dks362. Epub 2012 Sep 6. J Antimicrob Chemother. 2013. PMID: 22954492
235 results